Generic Medicine Info
Indications and Dosage
Adult: 40-80 mg tid.
Child: 1-6 years 20-40 mg 2-3 times daily; >6 years 40 mg tid.
May be taken with or without food.
Special Precautions
Patient with cardiac dysfunction. Renal and hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Cardiac disorders: Palpitation.
Gastrointestinal disorders: Gastrointestinal disturbance, nausea, vomiting, constipation, dry mouth.
Nervous system disorders: Vertigo, headache, dizziness.
Psychiatric disorders: Insomnia.
Vascular disorders: Orthostatic hypotension.
Patient Counseling Information
This drug may occasionally cause vertigo, if affected, do not drive or operate machinery.
Symptoms: Drowsiness, hypotension, and reduced gastric motility. Management: Symptomatic and supportive treatment.
Drug Interactions
May attenuate the antiparkinsonian action of levodopa.
Mechanism of Action: Drotaverine is a musculotropic antispasmodic agent which inhibits phosphodiesterase enzyme, causing increased cAMP levels thereby producing smooth muscle relaxation.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 1712095, Drotaverine. https://pubchem.ncbi.nlm.nih.gov/compound/Drotaverine. Accessed Nov. 22, 2023.

Store below 30°C. Protect from light.
MIMS Class
ATC Classification
A03AD02 - drotaverine ; Belongs to the class of papaverine and derivatives. Used in the treatment of functional bowel disorders.
Buckingham R (ed). Drotaverine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 25/09/2023.

Deolin (Unison). MIMS Thailand. http://www.mims.com/thailand. Accessed 25/09/2023.

Spamodyn (Noripharma Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 25/09/2023.

Disclaimer: This information is independently developed by MIMS based on Drotaverine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in